COVID-19 - January 7, 2021
Moderna’s COVID-19 vaccine authorized in the EU
The European Commission has granted a conditional marketing authorization (CMA) for COVID-19 Vaccine Moderna, allowing vaccination programs using the Moderna vaccine to be rolled out across the European Union. The authorization is based upon the recommendation of the European Medicines Agency (EMA) for use of the COVID-19 Vaccine Moderna for active immunization to prevent COVID-19 […]
COVID-19 - January 7, 2021
CureVac and Bayer join forces on COVID-19 vaccine candidate
Bayer has signed a collaboration and services agreement with CureVac, a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA). Under the terms of the agreement, Bayer will support the further development, supply and key territory operations of CureVac’s COVID-19 vaccine candidate CVnCoV. To this end, Bayer will contribute […]
COVID-19 - January 4, 2021
AstraZeneca’s COVID-19 vaccine authorised for emergency supply in the UK
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has provided authorisation for emergency supply of COVID-19 Vaccine AstraZeneca, formerly AZD1222, for the active immunisation of individuals 18 years or older. The authorisation recommends two doses administered with an interval of between four and 12 weeks. This regimen was shown in clinical trials to be safe […]
COVID-19 - December 21, 2020
Pfizer & BioNTech’s COVID-19 vaccine approved in the EU
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion to recommend the conditional marketing authorization (CMA) of the Pfizer-BioNTech COVID-19 Vaccine in individuals 16 years of age and older. “We are pleased with the Committee’s strong vote of confidence in our data,” says Albert Bourla, […]
COVID-19 - December 17, 2020
AstraZeneca to test combination of AZD1222 and Sputnik V vaccines
AstraZeneca and Russia’s Gamaleya Institute, which developed the Sputnik V vaccine, has signed a memorandum of intent on cooperation, reports Reuters. Russia’s RDIF sovereign wealth fund said this month AstraZeneca would start clinical trials to test a combination of its experimental COVID-19 vaccine with the Sputnik V shot to see if this can boost the […]
COVID-19 - December 17, 2020
Valneva initiates Phase 1/2 study of its vaccine candidate
Valneva SE has announced the initiation of a Phase 1/2 clinical study for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001. VLA2001 leverages the manufacturing platform of Valneva’s licensed Japanese encephalitis vaccine, IXIARO and is the first publicly announced inactivated vaccine against COVID-19 to commence clinical development in Europe. “Our teams have been working extremely hard […]
